Published in Medical Letter on the CDC and FDA, April 20th, 2008
"To create a system that will estimate the potential association between a serious adverse event and a medication early in its marketing cycle. All case reports of acute liver failure associated with pemoline and reported to the US FDA from 1975 through 1999 were reviewed. All published articles on pemoline-induced hepatotoxicity were reviewed, and the Naranjo adverse drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA